REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Additional Hetero Ring Containing > The Additional Hetero Ring Is One Of The Cyclos In A Polycyclo Ring System > Plural Hetero Atoms In The Polycyclo Ring System Plural Hetero Atoms In The Polycyclo Ring SystemPlural Hetero Atoms In The Polycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027189 - Use of known active ingredients as radical scavengers The invention relates to the use of certain proton pump inhibitors in the treatment of pathological manifestations induced or influenced by free radicals. ... 02/01/07 - 20070027188 - Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of structural Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient This invention also relates to the use of such compounds to provide a ... 01/25/07 - 20070021467 - Salts of omeprazole and esomeprazole ii The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention ... 01/11/07 - 20070010560 - Benzimidazole derivatives as raf kinase inhibitors The present invention relates to benzimidazole derivatives of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition ... 01/04/07 - 20070004779 - Process for producing crystal The present invention relates to a production method of a crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]benzimidazole.n′H2O (wherein n′ is about 0 to about 0.1) or a salt thereof, which characteristically includes crystallization from an organic solvent solution or suspension in which (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-benzimidazole.nH2O (wherein n is about 0.1 to about 1.0) or a salt ... 01/04/07 - 20070004778 - New salts of omeprazole and esomeprazole i The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to adamantan ammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and adamantan amine. The present invention also relates ... 12/28/06 - 20060293363 - Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1h-benzimidazoles Improved processes for preparing substituted 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazoles are disclosed. ... 12/21/06 - 20060287364 - Methods of prevention of infection with hiv/aids, venereal disease and influenza The invention includes methods for prophylaxis of at least one of infection with HIV/AIDS and venereal diseases, grippe/influenza. The method includes use of materials, in solution, cream, gel and/or tablet form, which possess virucidal and bactericidal characteristics. The method includes applying such materials to a mammal's skin and/or mucous membranes ... 12/14/06 - 20060281789 - Protein kinase inhibitors (wherein R1 represents substituted or unsubstituted aryl or a substituted or unsubstituted heterocyclic group) or a pharmaceutically acceptable salt thereof. ... 12/07/06 - 20060276513 - Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h- benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester Disclosed are polymorphs of the active substance 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2 -yl-amino]-propionic acid ethyl ester, the preparation thereof and the use thereof as pharmaceutical compositions. ... 11/30/06 - 20060270711 - Tenatoprazole salts and process of preparation thereof wherein X is Li, Na, Ca, K or Mg and to a process for the preparation thereof which comprises oxidizing a compound of formula (2) and isolating the salt (Li, Na) by treatment with the alkali hydroxide or exchanging the sodium salt of tenatoprazole with Mg++ or Ca++ cation. ... 11/23/06 - 20060264473 - Isoindolone compounds, compositions containing the same, and methods of use thereof for the treatment of viral infections related to the etiology of cancer Isoindolone derivatives, compositions containing the same, and methods of use thereof for the treatment or prophylaxis of viral infection are disclosed. ... 11/23/06 - 20060264472 - Derivatives of 6,7-dihydro-5h-imidazo[1,2-a] imidazole-3-sulfonic acid Derivatives of 6,7-dihydro-5H-imidazo[1,2-a]imidazole-3-sulfonic acid which exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease. ... 11/16/06 - 20060258716 - Methods and compositions for the treatment of helicobacter pylori-associated diseases using endoperoxide bridge-containing compounds The present invention relates to methods and compositions for treating or preventing pathological conditions associated with ferrous-dependent bacteria, such as, Helicobacter pylori in which high intracellular ferrous iron concentration is required for survival and pathogenesis. The compositions of the invention comprise endoperoxide bridge-containing compounds that specifically inhibit the growth of ... 11/09/06 - 20060252800 - Anti-leishmania agent The present invention is to provide a new anti-leishmania agent with fewer side effects, having a high cell proliferation-inhibiting effect to leishamia protozoa, and also easy to manufacture at a low cost. A compound wherein a heterocycle with a conjugated system and a nitrogen atom and a heterocycle with a ... 11/02/06 - 20060247278 - Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester The invention relates to new, physiologically acceptable salts of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate. ... 11/02/06 - 20060247277 - Polymorphs of s-omeprazole This invention relates to polymorphic forms of the S-enantiomer of omeprazole which is S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1Hbenzimidazole. The invention also relates to processes for preparing the polymorphic forms. More particularly, it relates to the preparation of two polymorphic forms of Someprazole, referred to as ‘Form I’ and ‘Form 1’ and pharmaceutical compositions that ... 10/26/06 - 20060241150 - P38 kinase inhibitor compositions and methods of using the same Methods of treating an individual who has been identified as having been infected with HIV are disclosed. Methods of treating an individual who is suspected of having been exposed to HIV are disclosed. Some methods disclosed comprise the step of administering to the individual an amount of a p38 inhibitor ... 10/19/06 - 20060235053 - Agents for the treatment of lower abdominal disorders The invention relates to the use of pantoprazole in the treatment of lower abdominal disorders. ... 10/19/06 - 20060235052 - Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses In the present invention there are disclosed new derivatives of dianhydrohexite mononitrate corresponding to formula (I), tautomers, pharmaceutically acceptable salts, prodrugs and solvates thereof as well as pharmaceutical compositions comprising these compounds and uses thereof. ... 10/05/06 - 20060223863 - Methods for treating hepatitis c In accordance with the present invention, compounds that inhibit viral replication, preferably Hepatitis C Virus (HCV) replication, have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the treatment or prevention of a viral infection are provided. In another aspect of the ... 09/28/06 - 20060217423 - Substituted sulfoxide compounds, methods for preparing the same and use thereof Disclosed are an optically pure compound having formula I, its pharmaceutically acceptable salt and its pharmaceutically acceptable solvate, and a use thereof in manufacturing medicaments and pharmaceutical compositions. A process for preparing the compound defined therein is also provided. ... 09/21/06 - 20060211737 - Benzene, pyridine, and pyridazine derivatives wherein R1, R2, R3, R4, R5, R6, R7, n, Q1, Q2, Q3, Y, and X1-X4 are as defined herein. Compounds of Formula I are useful in the treatment of diseases and/or conditions related to cell proliferation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical compositions ... 09/14/06 - 20060205791 - Pharmaceutical process and compounds prepared thereby The present invention relates to an improved process for the preparation of a sulfinyl compound of formula (I), or a pharmaceutically acceptable salt, hydrate or solvate thereof, from a sulfide compound of formula (II), wherein in both formulae (I) and (II) R1 and R3 are selected from the group consisting ... 09/07/06 - 20060199846 - Certain substituted ureas as modulators of kinase activity Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, crystal forms, chelates, non-covalent complexes, prodrugs, and mixtures thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided ... 08/17/06 - 20060183779 - Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof The invention relates to a new administration form for the oral application of the active substance ethyl 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionate and the pharmacologically acceptable salts thereof. ... 08/17/06 - 20060183778 - Osteogenesis-promotion enhancer and method of screening the same It is an object of the present invention to provide an excellent enhancer for an osteogenesis accelerator that can enhance the activity of BMP as an osteogenesis accelerator. Another object of the present invention is to provide a method of screening for a novel enhancer for an osteogenesis accelerator. The ... 08/10/06 - 20060178407 - Substituted pyridines and their uses The present invention is directed to substituted pyridines, methods for their preparation and methods for their use in the treatment and/or prevention of mast cell related conditions. ... 08/10/06 - 20060178406 - Process for production of sulfoxide derivatives or salts thereof in the amorphous state A process for producing sulfoxide derivatives or salts thereof in the amorphous state, characterized by heat-drying solvated crystals of a sulfoxide derivative or a salt thereof represented by the general formula (I): wherein R1 represents a hydrogen atom, a methoxy group, or a difluoromethoxy group; R2 represents a methyl group ... 08/03/06 - 20060173045 - Preventative or remedy for grinding The present invention provides a preventive or therapeutic agent for bruxism or bruxism-related diseases that contains as an active ingredient at least one selected from the group consisting of proton pump inhibitors, histamine H2 receptor antagonists, and acid pump antagonists. Examples of the proton pump inhibitors include rabeprazole, omeprazole, esomeprazole, ... 07/27/06 - 20060167058 - Ppar-activating compound wherein A represents an oxygen atom, a nitrogen atom, or a sulfur atom; R represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkyl-alkyl group, an aryl group, an aryl-alkyl group an aryl-oxy-alkyl group, a pyridyl-alkyl group, an alkoxycarbonyl-alkyl group, or a ... 07/27/06 - 20060167057 - Compounds for the treatment of cns and amyloid associated diseases Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing CNS and amyloid associated disease. Also described are methods, compounds, pharmaceutical compositions and kits for detecting, diagnosing, monitoring and treating or preventing CNS and amyloid associated disease. ... 07/27/06 - 20060167056 - Polymorphs of {5-[3-(4,6-difluoro-1h-benzoimidazol-2-yl)-1h-indazol-5-yl)-4-methyl-pyridin-3-ylmethyl}-ethyl-amine The present invention relates to novel polymorphic forms of of 3{5-[3-(4,6-Difluoro-1H-benzoimidazol-2-yl)-1H-indazol-5-yl]-4-methyl-pyridin-3-ylmethyl}-ethyl-amine, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity. ... 07/20/06 - 20060160863 - Polymorphic and amorphous forms of 2-{3-[(e)-2-(4,6-dimethyl-pyridin-2-yl)-vinyl]-1h-indazol-6-ylamino}-n-(4-hydroxy-but-2-ynyl)benzamide and pharmaceutical compositions made therewith, and to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions, to treat ophthalmic diseases, such as age related macular degeneration and other diseases associated with unwanted ocular angiogenesis. ... 07/20/06 - 20060160862 - Caspase inhibitors and uses thereof wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparting the compounds of the invention. ... 07/20/06 - 20060160861 - Novel nicotinamide pyridinureas as vascular endothelial growth factor (vegf) receptor kinase inhibitors The invention relates to novel nicotinamide pyridinureas as VEGF receptor kinase inhibitors, their production and use as pharmaceutical agents for preventing or treating diseases that are triggered by persistent angiogenesis. ... 07/20/06 - 20060160860 - Synthesis of polyamine compounds Each variable in this formula is defined in the specification. ... 07/06/06 - 20060148856 - Benzimidazole derivatives and their use for modulating the gabaa receptor complex This invention relates to novel benzimidazole derivatives of formula (I), pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABAA receptor complex, and in particular ... 07/06/06 - 20060148855 - Carboxamide derivatives or a pharmaceutically acceptable salt or solvate thereof, wherein P, W, X, Y, R2, R3, r and s are as defined in the specification, processes for preparing such compounds, pharmaceutical compositions comprising such compounds and their use in therapy. ... 07/06/06 - 20060148854 - Chemical compounds Benzimidazolyl-pyridine derivatives, which are useful as SGK-1 inhibitors are described herein. The described invention also includes methods of making such benzimidazolyl-pyridine derivatives as well as methods of using the same in the treatment of diseases mediated by inappropriate SGK-1 activity. ... 06/29/06 - 20060142346 - S-lansoprazole compositions and methods Methods and compositions are disclosed utilizing optically pure (−) lansoprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of lansoprazole. The optically pure (−) isomer is also useful for the treatment of gastroesophageal reflux. (−) Lansoprazole is ... 06/29/06 - 20060142345 - 3,5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation 3,5 disubstituted indazole compounds that modulate and/or inhibit cell proliferation, such as the activity of protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating CDK dependent diseases to modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic ... 06/22/06 - 20060135565 - Crystalline form of rabeprazole sodium Rabeprazole sodium in crystalline hydrate forms, a pharmaceutical composition containing them, their use in therapy, a process for their preparation, and the use thereof for the purification of rabeprazole sodium. ... 06/08/06 - 20060122233 - Rabeprazole calcium The present invention relates to calcium salts of rabeprazole and processes for preparing rabeprazole calcium. The invention also relates to pharmaceutical compositions that include the rabeprazole calcium and use of said compositions for the treatment or prevention of gastrointestinal ulcers ... 06/01/06 - 20060116402 - N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library are useful in providing compounds to assay for such therapeutically useful compounds. ... 05/25/06 - 20060111402 - Novel benzimidazole derivatives useful as selective androgen receptor modulators (sarms) The present invention is directed to novel benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor. ... 05/04/06 - 20060094763 - Polymorphic forms of 6-[2-(methylcarbomoyl) phenyl sulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole The present invention relates to novel polymorphic forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a hyperproliferative disorder or a mammalian disease condition mediated by protein kinase activity. ... 05/04/06 - 20060094762 - Magnesium salt of imidazole derivative Magnesium salts of rabeprazole, processes for preparing them, pharmaceutical compositions of the salts and their use in treatment or prevention of gastrointestinal ulcers are provided. ... 04/27/06 - 20060089386 - Novel process for substituted sulfoxides The present invention relates to a process for preparing substituted sulfoxides either as a single enantiomer or in an enantiomerically enriched form. Thus, racemic omeprazole is reacted with (S)-camphorsulfonyl chloride to form a diastereomeric mixture and the diastereomers are separated by fractional crystallization, followed by deprotection to give esomeprazole. ... 04/20/06 - 20060084682 - Thrombopoietin mimetics Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected ... 04/13/06 - 20060079560 - Crystalline form of omeprazole A novel crystalline form of the substrate known under the chemical name 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfiny]-1H-benzimidazole, and having the generic name omeprazole, hereinafter referred to as omeprozole form C, is disclosed. Further, a process for the preparation of omeprazole form C, a pharmaceutical formulation containing omeprazole form C in admixture with pharmaceutically acceptable ... 03/16/06 - 20060058355 - Method of treatment of cardiac and/or renal failure using a calcium channel blocker and an angiotensin converting enzyme inhibitor or an angiotensin ii receptor blocker Disclosed is a pharmaceutical composition comprising a calcium channel blocker and an angiotensin II receptor blocker or an angiotensin converting enzyme inhibitor. Also disclosed is a method of treating cardiovascular disease or renal disease comprising identifying a patient in need of such treatment, and administering a pharmaceutical composition disclosed herein ... 03/02/06 - 20060046998 - Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease The present invention relates to compositions and methods for initial treatment of GERD and LPRD using a proton pump inhibitor drug administered concomitantly with a histamine H2 receptor inhibitor, either transdermally or orally. ... 02/02/06 - 20060025451 - Novel pyrazole compounds as transforming growth factor (tgf) inhibitors Novel pyrazole compounds, including derivatives thereof, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use are described. The compounds of the present invention are potent; inhibitors of transforming growth factor (“TGF”)-β signaling pathway. They are useful in the treatment of various TGF-related disease states ... 02/02/06 - 20060025450 - Use of an h+, k+ -atpase inhibitor in the treatment of asthma The invention provides a method for the treatment of polyposis which comprises treating a subject suffering from polyposis with an H+, K+-ATPase inhibitor and, optionally, a glucocorticoid. The invention also relates to a pharmaceutical formulation for simultaneous, separate or sequential administration in the treatment of Widal's Syndrome and in the ... 01/19/06 - 20060014799 - Ft-raman spectroscopic measurement Fourier Transform Raman Spectroscopy (FT-Raman) determines the isomer ratio of chemical compositions. ... 01/19/06 - 20060014798 - Process for the preparation of sulphinyl derivatives by oxidation of the corresponding sulfides The present invention relates to a mild and industrially applicable process for preparing sulfinyl derivatives of Formula (II), useful as inhibitors of gastric acid secretion, comprising the selective oxidation of the corresponding sulfides of Formula (I), as represented in scheme (I) and (II) in which said oxidation is performed with ... 01/05/06 - 20060004057 - New compounds The novel optically pure compounds Na+, Mg2+, Li+, K+, Ca2+ and N+(R)4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole or (−)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well ... 12/29/05 - 20050288334 - Process for preparing optically pure active compounds The invention relates to a novel process for preparing an optically pure PPI having a sulfinyl structure using a chiral zirconium complex or a chiral hafnium complex. ... 12/22/05 - 20050282866 - Substituted indoles are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NFκB is involved. ... 12/08/05 - 20050272777 - Vanilloid receptor ligands and their use in treatments and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic ... 12/01/05 - 20050267160 - 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as well as pharmaceutical preparations that contain the new benzimidazole derivatives. ... 12/01/05 - 20050267159 - Magnesium complexes of s-omeprazole pharmaceutical compositions and processes of making the same. In formula (I), solva, solvb, and solvc represent solvent molecules where x and y are independently selected from integers 0 to 6, the sum of which is 4 or 6, while z is a positive rational number from 0 to 6. The ... 12/01/05 - 20050267158 - Polymorphic and amorphous forms of 2,5-dimethyl-2h-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((e)-2 pyridin-2-yl-vinyl)-1h-indazol-6-ylamino]-phenyl}-amide The invention provides several polymorphic forms and an amorphous form of 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid {2-fluoro-5-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylamino]-phenyl}-amide, pharmaceutical compositions containing such polymorphic or amorphous forms, and methods of using such pharmaceutical compositions to treat disease states mediated by protein kinases, such as cancer and other disease states associated with unwanted angiogenesis and/or cellular ... 12/01/05 - 20050267157 - Magnesium-s-omeprazole pharmaceutical compositions and processes of making the same. In formula (I), solva, solvb, and solvc represent solvent molecules where x and y are independently selected from integers 0 to 6, the sum of which is 4 or 6, while z is a positive rational number from 0 to 6. The ... 12/01/05 - 20050267156 - Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors wherein R1 is hexahydrofuro[2,3-b]furanyl, tetrahydrofuranyl, oxazolyl, thiazolyl, pyridinyl, or phenyl optionally substituted with one or more substituents independently selected from C1-6alkyl, hydroxy, amino, halogen, aminoC1-4alkyl and mono- or di(C1-4alkyl)amino; R2 is hydrogen or C1-6alkyl; L is a direct bond, —O—, C1-6alkanediyl-O— or —O—C1-6alkanediyl; R3 is phenylC1-4alkyl; R4 is C1-6alkyl; R5 ... 11/24/05 - 20050261348 - (1s,5s)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane is an effective analgesic agent The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor. ... 11/03/05 - 20050245578 - Polymorphs of pantoprazole sodium salt and process for the preparation thereof Novel crystalline forms of pantoprazole sodium salt solvate with ketone solvents, a process for the preparation thereof, the use of the forms for the purification of pantoprazol, pharmaceutical compositions therefrom and the use thereof in therapy. ... 10/27/05 - 20050239845 - Combination of proton pump inhibitor, buffering agent, and prokinetic agent Pharmaceutical compositions comprising a proton pump inhibitor, one or more buffering agent and a prokinetic agent are described. Methods are described for treating gastric acid related disorders, using pharmaceutical compositions comprising a proton pump inhibitor, a buffering agent, and a prokinetic agent. ... 10/27/05 - 20050239844 - Composition fo preventing secretion of immunoglobulin e-dependent histamine releasing factor The present invention relates to a composition for inhibiting the secretion of an immunoglobulin E (IgE)-dependent histamine-releasing factor, and pharmaceutical use thereof. The composition of the present invention contains a benzimidazolic compound having proton pump inhibitor activity, as an active ingredient. Furthermore, the composition of the present invention may contain ... 10/20/05 - 20050234104 - 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1h-benzimidazol-5-carbonyl)pyridin-2-ylamino]propionic acid ethylester methansulfonate and its use as medicament Ethyl 3-[(2-{[4-(hexyloxycarbonylaminoiminomethyl)phenylamino]methyl}-1-methyl-1H-benzimidazole-5-carbonyl)pyridin-2-ylamino]propionate methanesulfonate in the crystalline modifications I and II and as the hemihydrate and the use thereof as a pharmaceutical composition. ... 10/20/05 - 20050234103 - Crystalline forms of rabeprazole sodium The present invention relates to novel polymorphic forms of Rabeprazole sodium. The present invention also relates to methods of making polymorphic forms of Rabeprazole sodium. Achiphex7 (Rabeprazole sodium) is an inhibitor of the gastric proton pump. It causes dose-dependant inhibition of acid secretion and is useful as an antiulcer agent. ... 10/13/05 - 20050228026 - Benzimidazole compound crystal A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent. ... 10/06/05 - 20050222211 - S(-)rabeprazole compositions and methods Methods and compositions are disclosed utilizing optically pure S(−)rabeprazole for the treatment of ulcers in humans while substantially reducing the concomitant liability of adverse effects associated with the racemic mixture of rabeprazole. The optically pure S(−) isomer is also useful for the treatment of gastroesophageal reflux. S(−)rabeprazole is an inhibitor ... 10/06/05 - 20050222210 - Prodrugs of imidazole derivatives, for use as proton pump inhibitors in the treatment of e.g. peptic ulcers An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion ... 09/29/05 - 20050215595 - Indazole derivatives and methods for using the same wherein m, k, B, R1, R2 and R3 are those defined herein, and compositions comprising the same. Also provided are methods for preparing compounds of formula I and using the same in treating p38 mediated disorders in a patient. ... 09/22/05 - 20050209284 - Tec kinase inhibitors wherein Ar1, Ar2, R1, R2, R3, R4 and Xa are defined herein. The compounds of the invention inhibit Itk kinase and are therefore useful for treating diseases and pathological conditions involving inflammation, immunological disorders and allergic disorders. Also disclosed are processes for preparing these compounds and to pharmaceutical compositions comprising ... 09/15/05 - 20050203146 - Amino-benzazoles as p2y1 receptor inhibitors The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity. ... 08/25/05 - 20050187257 - Methods of treating sepsis in which n is 0, 1, 2, or 3; each of Ar1, Ar2, and Ar3, independently, is phenyl, pyridinyl, thienyl, furyl, or pyrrolyl; and each of R1, R2, R3, R4, R5, and R6, independently, is XYZ; or R1 and R2 together, R3 and R4 together, or R5 and R6 together ... 08/25/05 - 20050187256 - New compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation The present invention relates to an improved method for the synthesis of the (S)— or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide results ... 08/18/05 - 20050182102 - Pyridines and uses thereof The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells. ... 08/18/05 - 20050182101 - Prodrugs of proton pump inhibitors where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability. ... 08/18/05 - 20050182100 - Method of use A method for treatment of sleeping disturbance to obtain improvement of sleeping, wherein a therapeutically effective dose of esomeprazole or an alkaline salt thereof is administered to a patient suffering therefrom. The method is applicable for instance in patients suffering from gastroesophagal diseases (GERD). ... 08/18/05 - 20050182099 - Alkylammonium salts of omepazole and esomeprazole The present invention relates to new salts of omeprazole and esomeprazole respectively, i.e. salts of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole and the (S)-enantiomer thereof. More specifically, the present invention relates to alkylammonium salt of the compounds, formed by a reaction of omeprazole and esomeprazole respectively and an alkylamine with formula NR?1#191R?2#191R?3#191 wherein R?1#191 is ... 08/11/05 - 20050176774 - Ft-raman spectroscopic measurement Fourier Transform Raman Spectroscopy (FT-Raman) determines the isomer ratio of chemical compositions. ... 08/04/05 - 20050171162 - Crystals of benzimidazole compounds Crystals of (S)-2[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or salts thereof, useful as excellent antiulcer drugs. ... 07/28/05 - 20050165061 - Method for the purification of lansoprazole The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water. ... 07/28/05 - 20050165060 - Method for the purification of lansoprazole The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water. ... 07/28/05 - 20050165059 - Method for the purification of lansoprazole The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water. ... 07/21/05 - 20050159455 - 1,4-dihydropyridine and pyridine compounds as calcium channel blockers The present invention is directed in part towards methods of modulating the function of calcium channels with pyridine- or 1,4-dihydropyridine-based compounds. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pyridine- ... 07/14/05 - 20050154026 - Use of proton pump inhibitors for the treatment of noncardiac chest pain The invention relates to the use of proton pump inhibitors in the treatment of non-cardiac chest pain. ... 07/07/05 - 20050148634 - 1-n-aminobenzimidazole derivatives The compounds (I) according to the present invention do not bring about much individual differences in therapeutic effects despite the existence of individual differences in the CYP2C19 activity. At the same dose, they can hence bring about appropriate therapeutic effects for all patients. In addition, they are low in the ... 06/30/05 - 20050143423 - Prodrugs of proton pump inhibitors background of the invention where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability. ... 06/23/05 - 20050137233 - Prodrugs of 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carboxylic acid-(n-2-pyridyl-n-2-hydroxycarbonylethyl)-amide having thrombin-inhibiting activity. Exemplary are: 1-Methyl-2-[4-(N-hydroxyamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-ethoxycarbonylethyl)-amide, and 1-Methyl-2-[4-(N-methoxycarbonylamidino)-phenylaminomethyl]-benzimidazol-5-yl-carboxylic acid-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amide. ... 06/16/05 - 20050131026 - Use of proton pump inhibitors for the treatment of airway disorders The invention relates to the use of proton pump inhibitors in the treatment of airway disorders. ... 06/09/05 - 20050124662 - Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit unwanted cell proliferation. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical ... ### FreshPatents.com Support |